152 related articles for article (PubMed ID: 21210950)
1. Tissue factor pathway inhibitor and bacterial infection.
Maroney SA; Mast AE
J Thromb Haemost; 2011 Jan; 9(1):119-21. PubMed ID: 21210950
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia.
Van Den Boogaard FE; Brands X; Schultz MJ; Levi M; Roelofs JJ; Van 't Veer C; Van Der Poll T
J Thromb Haemost; 2011 Jan; 9(1):122-32. PubMed ID: 21029363
[TBL] [Abstract][Full Text] [Related]
3. Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia.
van den Boogaard FE; van 't Veer C; Roelofs JJ; Meijers JC; Schultz MJ; Broze GJ; van der Poll T
Thromb Haemost; 2015 Jul; 114(1):115-22. PubMed ID: 25832548
[TBL] [Abstract][Full Text] [Related]
4. Recombinant activated protein C attenuates coagulopathy and inflammation when administered early in murine pneumococcal pneumonia.
Schouten M; van 't Veer C; Roelofs JJ; Gerlitz B; Grinnell BW; Levi M; van der Poll T
Thromb Haemost; 2011 Dec; 106(6):1189-96. PubMed ID: 21901240
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and Safety of Local Treatment with Recombinant Human Tissue Factor Pathway Inhibitor in a Rat Model of Streptococcus pneumoniae Pneumonia.
van den Boogaard FE; Hofstra JJ; van 't Veer C; Levi MM; Roelofs JJ; van der Poll T; Schultz MJ
PLoS One; 2015; 10(5):e0127261. PubMed ID: 25992779
[TBL] [Abstract][Full Text] [Related]
6. Ceftriaxone pharmacokinetics in interleukin-10-treated murine pneumococcal pneumonia.
Wang E; Bergeron Y; Bergeron MG
J Antimicrob Chemother; 2005 May; 55(5):721-6. PubMed ID: 15772139
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia.
File TM
Clin Microbiol Infect; 2006 May; 12 Suppl 3():31-41. PubMed ID: 16669927
[TBL] [Abstract][Full Text] [Related]
8. Attacking the pneumococcus -- a hundred years' war.
Swartz MN
N Engl J Med; 2002 Mar; 346(10):722. PubMed ID: 11882726
[No Abstract] [Full Text] [Related]
9. Efficacy of β-Lactam-plus-Macrolide Combination Therapy in a Mouse Model of Lethal Pneumococcal Pneumonia.
Yoshioka D; Kajiwara C; Ishii Y; Umeki K; Hiramatsu K; Kadota J; Tateda K
Antimicrob Agents Chemother; 2016 Oct; 60(10):6146-54. PubMed ID: 27480866
[TBL] [Abstract][Full Text] [Related]
10. Levofloxacin-ceftriaxone combination attenuates lung inflammation in a mouse model of bacteremic pneumonia caused by multidrug-resistant Streptococcus pneumoniae via inhibition of cytolytic activities of pneumolysin and autolysin.
Majhi A; Adhikary R; Bhattacharyya A; Mahanti S; Bishayi B
Antimicrob Agents Chemother; 2014 Sep; 58(9):5164-80. PubMed ID: 24957840
[TBL] [Abstract][Full Text] [Related]
11. Plasma-derived human antithrombin attenuates ventilator-induced coagulopathy but not inflammation in a Streptococcus pneumoniae pneumonia model in rats.
Aslami H; Haitsma JJ; Hofstra JJ; Florquin S; Dos Santos C; Streutker C; Zhang H; Levi M; Slutsky AS; Schultz MJ
J Thromb Haemost; 2012 Mar; 10(3):399-410. PubMed ID: 22236057
[TBL] [Abstract][Full Text] [Related]
12. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
Davidson R; Cavalcanti R; Brunton JL; Bast DJ; de Azavedo JC; Kibsey P; Fleming C; Low DE
N Engl J Med; 2002 Mar; 346(10):747-50. PubMed ID: 11882730
[No Abstract] [Full Text] [Related]
13. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats.
Choi G; Hofstra JJ; Roelofs JJ; Rijneveld AW; Bresser P; van der Zee JS; Florquin S; van der Poll T; Levi M; Schultz MJ
Crit Care Med; 2008 Jan; 36(1):204-10. PubMed ID: 18090375
[TBL] [Abstract][Full Text] [Related]
14. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
Zhanel GG; Hoban DJ; Chan CK
N Engl J Med; 2002 Jul; 347(1):65-7; author reply 65-7. PubMed ID: 12102063
[No Abstract] [Full Text] [Related]
15. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
Ross JJ; Worthington MG; Gorbach SL
N Engl J Med; 2002 Jul; 347(1):65-7; author reply 65-7. PubMed ID: 12097545
[No Abstract] [Full Text] [Related]
16. Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia.
de Porto AP; Liu Z; de Beer R; Florquin S; de Boer OJ; Hendriks RW; van der Poll T; de Vos AF
Mol Med; 2019 Jan; 25(1):3. PubMed ID: 30646846
[TBL] [Abstract][Full Text] [Related]
17. Impredictable susceptibility for cephalosporins in penicillin resistant Streptococcus pneumoniae.
Verhaegen J; Vandeven J; Verbiest N; Fossion M; Mengeot PM; Amougou M; Verbist L
Acta Clin Belg; 1997; 52(2):116-7. PubMed ID: 9204588
[No Abstract] [Full Text] [Related]
18. [New quinolones for the treatment of community-acquired pneumonia--pro].
Zimmerli S
Dtsch Med Wochenschr; 2003 May; 128(19):1070. PubMed ID: 12736859
[No Abstract] [Full Text] [Related]
19. Reply to: Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
Rubinstein E
J Antimicrob Chemother; 2003 May; 51(5):1307-8; author reply 1308-9. PubMed ID: 12697636
[No Abstract] [Full Text] [Related]
20. [New quinolones for the treatment of community-acquired pneumonia--contra].
Egger M
Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
[No Abstract] [Full Text] [Related]
[Next] [New Search]
